These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29979855)

  • 1. [In process].
    Reisdorf S
    Med Monatsschr Pharm; 2017 Jun; 40(6):271-3. PubMed ID: 29979855
    [No Abstract]   [Full Text] [Related]  

  • 2. Application of PCSK9 Inhibitors in Practice: Challenges and Opportunities.
    Kaufman TM; Duell PB; Purnell JQ; Wójcik C; Fazio S; Shapiro MD
    Circ Res; 2017 Aug; 121(5):499-501. PubMed ID: 28819040
    [No Abstract]   [Full Text] [Related]  

  • 3. JAMA PATIENT PAGE. PCSK9 Inhibitors for Treating High Cholesterol.
    Jin J
    JAMA; 2015 Dec; 314(21):2320. PubMed ID: 26624842
    [No Abstract]   [Full Text] [Related]  

  • 4. [Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target].
    Guijarro C; Ruilope LM
    Med Clin (Barc); 2015 Jul; 145(2):67-9. PubMed ID: 26004275
    [No Abstract]   [Full Text] [Related]  

  • 5. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.
    Kazi DS; Penko J; Coxson PG; Moran AE; Ollendorf DA; Tice JA; Bibbins-Domingo K
    JAMA; 2017 Aug; 318(8):748-750. PubMed ID: 28829863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurocognitive performance after PCSK9 inhibitor therapy: Current state of the evidence.
    Stamerra CA; Di Giosia P; Giorgini P; De Feo M; Grassi D; Ferri C; Sahebkar A
    J Neurosci Res; 2018 May; 96(5):762-764. PubMed ID: 29152786
    [No Abstract]   [Full Text] [Related]  

  • 7. Economics of lipid lowering with HMG CoA reductase inhibitors.
    Illingworth DR
    Clin Cardiol; 1995 Jun; 18(6):295, 363. PubMed ID: 7664501
    [No Abstract]   [Full Text] [Related]  

  • 8. PCSK9 inhibitors- A new age in lipid management?
    Grant PJ
    Diab Vasc Dis Res; 2017 May; 14(3):171. PubMed ID: 28467196
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of Hypercholesterolemia in 2015.
    Aronow WS
    Am J Ther; 2017; 24(2):e121-e129. PubMed ID: 26422823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inconsistent Guideline Recommendations for Cardiovascular Prevention and the Debate About Zeroing in on and Zeroing LDL-C Levels With PCSK9 Inhibitors.
    Ioannidis JPA
    JAMA; 2017 Aug; 318(5):419-420. PubMed ID: 28738115
    [No Abstract]   [Full Text] [Related]  

  • 11. From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications.
    Navarese EP; Kołodziejczak M; Dimitroulis D; Wolff G; Busch HL; Devito F; Sionis A; Ciccone MM
    Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):44-53. PubMed ID: 27533061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [PCSK9 inhibitors. A new approach for treatment of hypercholesterolemia].
    Saußele T
    Med Monatsschr Pharm; 2015 Jul; 38(7):250-7. PubMed ID: 26364362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The year in cardiology 2015: prevention.
    Chapman MJ; Blankenberg S; Landmesser U
    Eur Heart J; 2016 Feb; 37(6):510-9. PubMed ID: 26726043
    [No Abstract]   [Full Text] [Related]  

  • 14. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial.
    Katsiki N; Athyros VG; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Sep; 74():43-46. PubMed ID: 28477848
    [No Abstract]   [Full Text] [Related]  

  • 15. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk.
    Milionis H; Barkas F; Ntaios G; Papavasileiou V; Vemmos K; Michel P; Elisaf M
    Eur J Intern Med; 2016 Oct; 34():54-57. PubMed ID: 27363304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inhibitors of PCSK9].
    Petrova-Slater I; Denegri A; Pasotti E; Rossi MG; Spirk D; Riesen WF; Moccetti T; Moccetti M
    Rev Med Suisse; 2017 Apr; 13(558):821-825. PubMed ID: 28727332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proprotein Convertase Subtilisin/Kexin Type 9 Antibody and Statin-Associated Autoimmune Myopathy.
    de Dios García-Díaz J; Corral-Bueno IM; Mesa-Latorre JM; Lozano-Durán C; Hernández-Ahijado C
    Ann Intern Med; 2019 Jul; 171(1):68-69. PubMed ID: 30776798
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.
    Teramoto T; Kondo A; Kiyosue A; Harada-Shiba M; Ishigaki Y; Tobita K; Kawabata Y; Ozaki A; Baccara-Dinet MT; Sata M
    Lipids Health Dis; 2017 Jun; 16(1):121. PubMed ID: 28623954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [PCSK9 monoclonal antibody inhibition: current evidence and future perspectives of lipid-lowering therapy according to the available results from the ODYSSEY program].
    Lettino M
    G Ital Cardiol (Rome); 2015 Apr; 16(4):211-6. PubMed ID: 25959756
    [No Abstract]   [Full Text] [Related]  

  • 20. Challenges in Oral Lipid-lowering Therapy: Position Document of the Spanish Society of Cardiology.
    Anguita Sánchez M; Castro Conde A; Cordero Fort A; García-Moll Marimón X; Gómez Doblas JJ; González-Juanatey JR; Lidón Corbi RM; López-Sendón JL; Mostaza Prieto J; Rodríguez Padial L
    Rev Esp Cardiol (Engl Ed); 2016 Nov; 69(11):1083-1087. PubMed ID: 27650859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.